China's WuXi XDC jumps to 20-month high on robust earnings forecast

WuXi XDC Cayman

23/07/2025 03:49

** Shares of WuXi XDC Cayman Inc 2268.HK, a Chinese antibody drug conjugates research, development and manufacturing services provider, jump 14.5% to HK$56.55, their highest level since debut in November 2023

** Stock marks its biggest intraday pct gain since July 31, 2024 and on track to snap three straight sessions of losses, if current trend continues

** Top pct gainer in healthcare index .HSCIH, which is up 1.2%

** Co expects H1 net profit to increase more than 50% y/y, with revenue up over 60% y/y, due to growth of downstream demand in antibody drug conjugate and broader bioconjugate industry, among others

** Hang Seng Biotech Index .HSHKBIO rises 1.1%, benchmark Hang Seng Index .HSI climbs 0.6%

** YTD, stock up 81.4%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))